Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    FDA_Warning_Letters, Import_Alerts_&_EU_Non-Compliances_in_2019
    X

    Find Drugs for Pulmonary/Respiratory Diseases in Phase I Clinical Development

    A collaboration with SCORR Marketing

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    Country filter
      News Type filter
        Company filter
          Product Type filter
            Deal Size filter
              refresh

              Product Type

              Companies

              TFF Pharmaceuticals

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED STATES United States

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Drug Discovery Chemistry

              Participation Not Confirmed

              Update your events

              TFF Pharmaceuticals Announces Phase 1 Clinical Trial Progress for Voriconazole Inhalation Powder

              Contact the Supplier

              Lead Product(s): Voriconazole

              Therapeutic Area: Pulmonary/Respiratory Diseases

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 19, 2020

              Details:

              Successfully completes single ascending dose phase of first clinical study in healthy subjects for a direct-to-lung, Thin Film Freezing (TFF) dry-powder formulation.

              BioDelivery Sciences

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED STATES United States

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Drug Discovery Chemistry

              Participation Not Confirmed

              Update your events

              BioDelivery Sciences Announces Phase I Clinical Trial Results at the American Academy of Pain Medicine’s 36th Annual Meeting

              Contact the Supplier

              Lead Product(s): Buprenorphine

              Therapeutic Area: Pulmonary/Respiratory Diseases

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable February 27, 2020

              Details:

              BELBUCA effect on respiratory drive was comparable to placebo at all doses tested.The effect of immediate release oral oxycodone HCl resulted in a dose-dependent decrease in respiratory drive.

              Algernon Pharmaceuticals

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              CANADA Canada

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Drug Discovery Chemistry

              Participation Not Confirmed

              Update your events

              Algernon Pharmaceuticals Appoints Novotech as CRO for First Phase 2 Trial and Announces Novotech’s $220K Equity Investment

              Contact the Supplier

              Lead Product(s): Ifenprodil Tartrate

              Therapeutic Area: Pulmonary/Respiratory Diseases

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 17, 2020

              Details:

              Algernon Pharma has appointed Novotech as the contract research organization for the its upcoming Phase 2 idiopathic pulmonary fibrosis and chronic cough study for the drug candidate NP-120.

              Pulmatrix

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED STATES United States

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Drug Discovery Chemistry

              Participation Not Confirmed

              Update your events

              Pulmatrix Announces Research Collaboration with Nocion Therapeutics to Explore Inhaled Drug Delivery Technologies

              Contact the Supplier

              Lead Product(s): PUR1800

              Therapeutic Area: Pulmonary/Respiratory Diseases

              Highest Development Status: Phase I Product Type: Undisclosed

              Partner/Sponsor/Collaborator: Nocion Therapeutics

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration January 06, 2020

              Details:

              The collaboration will leverage Pulmatrix's iSPERSE™ platform and expertise in seeking to transform promising assets to improve drug delivery and safety profiles.

              Pulmatrix

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED STATES United States

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Drug Discovery Chemistry

              Participation Not Confirmed

              Update your events

              Pulmatrix Announces Kinase Inhibitor Licensing Agreement with Lung Cancer Initiative at Johnson & Johnson

              Contact the Supplier

              Lead Product(s): PUR1800

              Therapeutic Area: Pulmonary/Respiratory Diseases

              Highest Development Status: Phase I Product Type: Undisclosed

              Partner/Sponsor/Collaborator: Johnson & Johnson Enterprise Innovation

              Deal Size: $100.2 million Upfront Cash: $7.2 million

              Deal Type: Licensing Agreement January 02, 2020

              Details:

              Through the agreement, the Lung Cancer Initiative gains an option to access a portfolio of narrow spectrum kinase inhibitors,the intended for development in lung cancer interception. the ongoing Phase 1b study of RV1162/PUR1800 in stable COPD patients.

              PharmaCompass__DigitalAd